BR112017004008A2 - polipeptídeo recombinante, sequência de ácido nucleico, célula hospedeira, bionanopartícula, métodos para produção de uma bionanopartícula e para tratamento ou prevenção do vírus da dengue, e, vacina. - Google Patents

polipeptídeo recombinante, sequência de ácido nucleico, célula hospedeira, bionanopartícula, métodos para produção de uma bionanopartícula e para tratamento ou prevenção do vírus da dengue, e, vacina.

Info

Publication number
BR112017004008A2
BR112017004008A2 BR112017004008-5A BR112017004008A BR112017004008A2 BR 112017004008 A2 BR112017004008 A2 BR 112017004008A2 BR 112017004008 A BR112017004008 A BR 112017004008A BR 112017004008 A2 BR112017004008 A2 BR 112017004008A2
Authority
BR
Brazil
Prior art keywords
bionanoparticle
vaccine
treating
recombinant polypeptide
dengue virus
Prior art date
Application number
BR112017004008-5A
Other languages
English (en)
Inventor
Khanna Navin
RAMASAMY Viswanathan
Original Assignee
International Centre For Genetic Engineering And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Centre For Genetic Engineering And Biotechnology filed Critical International Centre For Genetic Engineering And Biotechnology
Publication of BR112017004008A2 publication Critical patent/BR112017004008A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

a invenção provê um polipeptídeo recombinante que compreende o domínio ediii de cada um dos sorotipos do vírus da dengue denv-1, denv-2, denv-3 e denv-4 ligados ao n-terminal de hbsag.
BR112017004008-5A 2014-09-01 2015-08-21 polipeptídeo recombinante, sequência de ácido nucleico, célula hospedeira, bionanopartícula, métodos para produção de uma bionanopartícula e para tratamento ou prevenção do vírus da dengue, e, vacina. BR112017004008A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2478/DEL/2014 2014-09-01
IN2478DE2014 2014-09-01
PCT/IB2015/056352 WO2016034974A1 (en) 2014-09-01 2015-08-21 Vaccine

Publications (1)

Publication Number Publication Date
BR112017004008A2 true BR112017004008A2 (pt) 2018-01-23

Family

ID=55439184

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004008-5A BR112017004008A2 (pt) 2014-09-01 2015-08-21 polipeptídeo recombinante, sequência de ácido nucleico, célula hospedeira, bionanopartícula, métodos para produção de uma bionanopartícula e para tratamento ou prevenção do vírus da dengue, e, vacina.

Country Status (18)

Country Link
US (3) US10189877B2 (pt)
EP (2) EP3685852A1 (pt)
JP (3) JP6983653B2 (pt)
CN (1) CN107074968B (pt)
BR (1) BR112017004008A2 (pt)
CA (1) CA2959280C (pt)
CY (1) CY1123664T1 (pt)
ES (1) ES2821480T3 (pt)
HR (1) HRP20201523T1 (pt)
HU (1) HUE053284T2 (pt)
LT (1) LT3188755T (pt)
MX (2) MX2017002621A (pt)
MY (1) MY201688A (pt)
PL (1) PL3188755T3 (pt)
PT (1) PT3188755T (pt)
RS (1) RS61000B1 (pt)
SI (1) SI3188755T1 (pt)
WO (1) WO2016034974A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074968B (zh) * 2014-09-01 2021-03-12 国际遗传工程和生物技术中心 疫苗
US11793873B2 (en) 2017-05-10 2023-10-24 University Of Massachusetts Bivalent dengue/hepatitis B vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
KR100251505B1 (ko) 1991-11-16 2000-05-01 장 스테판느 말라리아원충으로부터의 cs 및 hbsag 사이의 혼성 단백질(hybrid protein between cs from plasmodium and hbsag)
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
WO2007034507A2 (en) * 2005-09-20 2007-03-29 International Centre For Genetic Engineering And Biotechnology Tetravalent dengue specific domain iii based chimeric recombinant protein
WO2008152652A2 (en) * 2007-06-12 2008-12-18 International Centre For Genetic Engineering And Biotechnology A dengue envelope domain iii-based tetravalent protein vaccine
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
CN101962411B (zh) * 2009-07-24 2012-09-05 中国疾病预防控制中心病毒病预防控制所 登革病毒血清学早期诊断试剂
EP2571990A4 (en) * 2010-05-21 2013-11-20 Univ Pittsburgh UNIVERSAL DENGUE VIRUS SEQUENCES AND METHOD FOR THEIR USE
CN103193870B (zh) * 2013-04-22 2014-10-22 中国人民解放军第三军医大学 一种登革病毒简并疫苗及其应用
CN107074968B (zh) * 2014-09-01 2021-03-12 国际遗传工程和生物技术中心 疫苗

Also Published As

Publication number Publication date
MX2021006543A (es) 2021-10-13
CA2959280A1 (en) 2016-03-10
US20190194261A1 (en) 2019-06-27
US10815280B2 (en) 2020-10-27
MX2017002621A (es) 2017-07-28
CA2959280C (en) 2023-09-26
PL3188755T3 (pl) 2021-01-25
EP3188755A1 (en) 2017-07-12
US10189877B2 (en) 2019-01-29
US20210122787A1 (en) 2021-04-29
WO2016034974A1 (en) 2016-03-10
HUE053284T2 (hu) 2021-06-28
US11945842B2 (en) 2024-04-02
EP3685852A1 (en) 2020-07-29
CN107074968A (zh) 2017-08-18
RS61000B1 (sr) 2020-11-30
JP6985458B2 (ja) 2021-12-22
LT3188755T (lt) 2020-12-28
CN107074968B (zh) 2021-03-12
ES2821480T3 (es) 2021-04-26
PT3188755T (pt) 2020-09-29
JP2022031791A (ja) 2022-02-22
JP7333373B2 (ja) 2023-08-24
JP2020162611A (ja) 2020-10-08
EP3188755B1 (en) 2020-08-05
HRP20201523T1 (hr) 2021-03-05
US20170240601A1 (en) 2017-08-24
JP2017526366A (ja) 2017-09-14
SI3188755T1 (sl) 2021-03-31
JP6983653B2 (ja) 2021-12-17
MY201688A (en) 2024-03-13
CY1123664T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BR112018007017A2 (pt) polipeptídeos
BR112018000604A2 (pt) moléculas de anticorpo que ligam cd45
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
MX2016016722A (es) Coronavirus.
EA201890527A1 (ru) Терапевтические вакцины против hpv18
BR112016022841A2 (pt) cadeia j modificada
MX2021008318A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
MX2017008096A (es) Pestivirus.
PH12017500450A1 (en) Flavivirus virus like particle
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
BR112016019176A2 (pt) anticorpos il-21
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
BR112018015453A2 (pt) vírus atenuado da bronquite infecciosa
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
BR112016017046A2 (pt) Anticorpos contra glicoproteína f de vírus hendra e nipah
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
MX2016013584A (es) Parvovirus porcino.
BR112015023738B8 (pt) Vacinas de nucleoproteina influenza

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]